Plexxikon's PLX3397 to join I-SPY 2

Plexxikon Inc. said its PLX3397 will be included in the Phase II I-SPY 2 trial to treat patients with newly diagnosed, locally advanced breast cancer. PLX3397 will enter the ongoing trial, which is managed by QuantumLeap Healthcare Collaborative, in 1H15.

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) acquired Plexxikon Inc. in 2011 (see BioCentury Extra, Feb. 28, 2011). ...